NX1NEXALIS THERAPEUTICS LTD
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 31 July 2026, 23:07 | Jun26 Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002 | |
| 31 July 2026, 23:06 | Jun26 Quarterly Activities Report | Other | MS | 19007 | |
| 30 July 2026, 21:02 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 15 July 2026, 01:13 | Change of Director's Interest Notice - Sean Williams | Director Interests | — | 02009 | |
| 15 July 2026, 01:12 | Change of Director's Interest Notice - Darryl Davies | Director Interests | — | 02009 | |
| 15 July 2026, 01:10 | Notification of cessation of securities - NX1 | Other | — | 06027 | |
| 15 July 2026, 01:10 | Notification regarding unquoted securities - NX1 | Other | — | 06021 | |
| 15 July 2026, 01:06 | Issue of director share rights post shareholder approval | Securities Administration | — | 06009 | |
| 6 July 2026, 21:48 | Update on Funding Facility and Clinical Program | Capital Raising | MS | 03014, 03022, 11001 | |
| 26 June 2026, 01:52 | Director Appointment/Resignation | Company Administration | — | 02008, 02010, 12001 | |
| 30 May 2026, 04:23 | 2026 AGM results | Meetings & Governance | — | 08003 | |
| 30 May 2026, 02:14 | 2026 AGM slides | Presentations | — | 03026, 15002 | |
| 28 May 2026, 19:48 | Reinstatement to Official Quotation | Reinstatement | MS | 09002 | |
| 28 May 2026, 19:48 | Binding Letter of Intent to replace existing $53m facility | Capital Raising | MS | 03022, 06009, 11001 | |
| 26 May 2026, 20:34 | Suspension from Quotation | Trading Halt / Suspension | MS | 09001 | |
| 22 May 2026, 19:38 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 14 May 2026, 21:33 | Phase 1 IRX-616a Last Patient Last Dose | Company Update | — | 11001 | |
| 13 May 2026, 23:10 | Director Appointment/Resignation | Company Administration | — | 02008, 02010, 12001 | |
| 1 May 2026, 03:13 | 2026 AGM - Sample Proxy Form | Meetings & Governance | — | 08004 | |
| 1 May 2026, 03:12 | 2026 AGM - Access Letter | Meetings & Governance | — | 08001, 16002 | |
| 1 May 2026, 03:10 | Notice of Annual General Meeting | Presentations | — | 08001, 14014 | |
| 1 May 2026, 00:40 | Mar26 Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001 | |
| 1 May 2026, 00:40 | Mar26 Quarterly Activities Report | Other | MS | 19006 | |
| 28 Apr 2026, 19:25 | Phase 1 IRX-616a Trial Advances to Final Cohort | Company Update | — | 11001 | |
| 23 Apr 2026, 19:41 | US Policy Market Advancement Supports SRX-25 TRD Treatment | Company Update | — | 11001 | |
| 20 Apr 2026, 19:59 | Significant Milestone - First Patient Screened IRX-211 Ph2 | Company Update | MS | 11001 | |
| 17 Apr 2026, 19:50 | Phase 1 IRX-616a Trial Advances - Positive Safety Review | Company Update | — | 11001 | |
| 1 Apr 2026, 04:59 | 2025 Annual Report | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 1 Apr 2026, 04:41 | 2025 Corporate Governance Statement and 4G | Company Administration | — | 03024, 03025 | |
| 26 Mar 2026, 01:34 | Nexalis to present at the NWR Virtual Healthcare Conference | Company Administration | — | 12008 | |
| 19 Mar 2026, 20:22 | First patient dosed in IRX-616a Phase 1 trial | Company Update | MS | 11001 | |
| 4 Mar 2026, 22:26 | First eligible participant screened - phase 1 IRX-616a study | Company Update | MS | 11001 | |
| 28 Feb 2026, 04:34 | Preliminary Final Report | Financial Results | MS | 03003 | |
| 23 Feb 2026, 21:32 | Cleansing Notice | Securities Administration | — | 06018 | |
| 23 Feb 2026, 21:32 | Application for quotation of securities - NX1 | Other | — | 06020 | |
| 21 Feb 2026, 00:54 | Proposed issue of securities - NX1 | Securities Administration | — | 06013 | |
| 21 Feb 2026, 00:50 | Issue of shares to satisfy Advisory/Lead Manager Services | Securities Administration | — | 06009 | |
| 18 Feb 2026, 02:45 | Cleansing Notice | Securities Administration | — | 06018 | |
| 17 Feb 2026, 22:13 | Notification regarding unquoted securities - NX1 | Other | — | 06021 | |
| 17 Feb 2026, 22:12 | Proposed issue of securities - NX1 | Securities Administration | — | 06013 | |
| 17 Feb 2026, 22:05 | Change of Director's Interest Notice x3 | Director Interests | — | 02009 | |
| 17 Feb 2026, 22:00 | Notification regarding unquoted securities - NX1 | Other | — | 06021 | |
| 17 Feb 2026, 22:00 | Notification regarding unquoted securities - NX1 | Other | — | 06021 | |
| 17 Feb 2026, 21:44 | Application for quotation of securities - NX1 | Other | — | 06020 | |
| 17 Feb 2026, 21:44 | ALLOTMENT OF SECURITIES FOLLOWING SHAREHOLDER APPROVAL | Capital Raising | — | 06003, 06009 |
1–45 of 45
1 / 1